Company intelligence / Profile preview

SciClone Pharmaceuticals International (Cayman) Development Limited

George Town, Grand Cayman, Cayman Islands

Ownership: Private
Employees: ~860
Development stage: Other

Overview

PT-112, a DNA inhibitor small molecule therapy, is being evaluated in Phase 1/2 trials for advanced solid tumors and non-small cell lung cancer in combination with docetaxel. Completed and ongoing studies are mainly at early clinical stages, with indications in thymic carcinoma and lung cancer.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Promontory Therapeutics, Inc. (originator of PT-112)National Cancer Institute (active org on trial)

Beyond the preview

Go deeper on SciClone Pharmaceuticals International (Cayman) Development Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciClone Pharmaceuticals International (Cayman) Development Limited.

Explore the full profile